Orgenesis Stock Price, News & Analysis (OTCMKTS:ORGS)

$4.50 0.20 (4.65 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$5.00
Today's Range$4.50 - $5.20
52-Week Range$2.76 - $11.76
Volume9,902 shs
Average Volume5,372 shs
Market Capitalization$42.45 million
P/E RatioN/A
Dividend YieldN/A

About Orgenesis (OTCMKTS:ORGS)

Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.

Receive ORGS News and Ratings via Email

Sign-up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Business Services


Debt-to-Equity Ratio0.43%
Current Ratio0.32%
Quick Ratio0.27%


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.39 million
Price / Sales6.95
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares9,870,000

Orgenesis (OTCMKTS:ORGS) Frequently Asked Questions

What is Orgenesis' stock symbol?

Orgenesis trades on the OTCMKTS under the ticker symbol "ORGS."

Who are some of Orgenesis' key competitors?

Who are Orgenesis' key executives?

Orgenesis' management team includes the folowing people:

  • Vered Caplan, Chairman of the Board, Chief Executive Officer, President; Chief Executive Officer of Orgenesis Maryland Inc. (Age 46)
  • Neil T. Reithinger CPA, Chief Financial Officer, Treasurer, Secretary (Age 46)
  • Sarah Ferber Ph.D., Chief Scientific Officer (Age 60)
  • Yaron Adler, Director (Age 44)
  • Hugues Bultot, Director
  • David Sidransky M.D., Director (Age 56)
  • Guy Yachin, Director (Age 47)

Who owns Orgenesis stock?

Orgenesis' stock is owned by a number of of institutional and retail investors. Top institutional investors include BELENGER OLIVIER (8.92%), THEODORUS SCA (8.92%) and THEODORUS II SA (8.92%). View Institutional Ownership Trends for Orgenesis.

How do I buy Orgenesis stock?

Shares of Orgenesis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Orgenesis' stock price today?

One share of Orgenesis stock can currently be purchased for approximately $4.50.

How big of a company is Orgenesis?

Orgenesis has a market capitalization of $42.45 million and generates $6.39 million in revenue each year. Orgenesis employs 80 workers across the globe.

How can I contact Orgenesis?

Orgenesis' mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 480-659-6404 or via email at [email protected]

MarketBeat Community Rating for Orgenesis (ORGS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  6 (Vote Outperform)
Underperform Votes:  7 (Vote Underperform)
Total Votes:  13
MarketBeat's community ratings are surveys of what our community members think about Orgenesis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Orgenesis (OTCMKTS:ORGS) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Earnings History for Orgenesis (OTCMKTS:ORGS)

No earnings announcements for this company have been tracked by


Orgenesis (OTCMKTS:ORGS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.13 EPS
Next Year EPS Consensus Estimate: $-0.04 EPS


Dividend History for Orgenesis (OTCMKTS:ORGS)

No dividend announcements for this company have been tracked by

Insider Trades

Orgenesis (OTCMKTS ORGS) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 0.03%
Insider Trades by Quarter for Orgenesis (OTCMKTS:ORGS)

Orgenesis (OTCMKTS ORGS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/11/2017Sca TheodorusInsiderSell5,000,000$0.25$1,250,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Orgenesis (OTCMKTS ORGS) News Headlines


SEC Filings

Orgenesis (OTCMKTS:ORGS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Orgenesis (OTCMKTS ORGS) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.